Bilateral Association Between Atopic Dermatitis® and Alopecia Areata: A Systematic Review and Meta-Analysis

Sun, Rong; Kong, Deqi

doi:10.1089/derm.2023.0114

Cited by 6 publications

(4 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Atopic dermatitis (AD), a chronic inflammatory skin condition characterized by pruritus and eczematous lesions, shares immunological pathways with AA, potentially influencing disease outcomes. Studies have reported increased prevalence of AD among AA patients, indicating a possible association between the two conditions ( 24 ). Furthermore, shared genetic susceptibility loci and dysregulated immune responses, particularly involving T-helper cell subsets and cytokine profiles, may contribute to the co-occurrence of AA and AD.…”

Section: Discussionmentioning

confidence: 99%

Disease burden, clinical management and unmet treatment need of patients with moderate to severe alopecia areata; consensus statements, insights, and practices from CERTAAE (Central/Eastern EU, Russia, Türkiye AA experts) Delphi panel

Rudnicka,

Trzeciak,

Alpsoy

et al. 2024

Front. Med.

View full text Add to dashboard Cite

ObjectivesThis study aims to update the understanding of Alopecia Areata (AA) in Poland, Czechia, Russia, and Türkiye, focusing on the disease burden, clinical management, and patient journey. It seeks to establish a consensus on optimal management strategies for AA in these regions.MethodsA modified 2-round Delphi panel was conveyed with 23 Dermatologists (Russia; 4, Türkiye; 7, Poland; 6, and Czechia; 6). The Delphi questionnaire consisted of 61 statements and 43 questions designed to obtain an overall understanding of the perception and acceptance of available information regarding the care of patients with alopecia areata.ResultsThe study revealed that moderate-to-severe AA significantly impacts patients’ and their families’ QoL, consistent with previous studies. AA was found to cause more substantial impairment when additional lesions appeared in visible areas besides the scalp. Work and productivity impairment were notably higher in adults with moderate-to-severe AA. Diagnostic consensus highlighted the importance of skin biopsies and trichoscopy, while the need for more practical severity scoring systems was emphasized. Current treatments, including topical therapies, corticosteroids, and systemic immune modifiers, were deemed insufficient, highlighting the unmet medical need.ConclusionThe Delphi study underscores a significant disease burden and unmet medical needs in patients with moderate-to-severe AA. It highlights the necessity of access to novel treatments and further research to develop more effective therapies with a tolerable safety profile. The findings align with global research, emphasizing the psychosocial impact of AA and the need for standardized, effective treatment protocols.

show abstract

Section: Discussionmentioning

confidence: 99%

Disease burden, clinical management and unmet treatment need of patients with moderate to severe alopecia areata; consensus statements, insights, and practices from CERTAAE (Central/Eastern EU, Russia, Türkiye AA experts) Delphi panel

Rudnicka,

Trzeciak,

Alpsoy

et al. 2024

Front. Med.

View full text Add to dashboard Cite

show abstract

“…Приводятся данные, что нарушения барьерной функции при АтД не только имеют значение в возникновении других аллергозов, но и могут способствовать развитию такого аутоиммунного заболевания, как гнездная алопеция, безусловно, при наличии генетической предрасположенности [35]. Текущие исследования взаимосвязи АтД и гнездной алопеции указывают на частую ассоциацию и взаимное отягчаю щее влияние этих заболеваний, которые рассматриваются как коморбидные [36,37]. Иммунный ответ 2-го типа, играю щий основную роль в патогенезе АтД, может участвовать в патофизиологических механизмах развития гнездной алопеции при сочетании этих заболеваний, обуславливая формирование определенного иммунофенотипа атопической гнездной алопеции [38].…”

Section: патогенетическая роль нарушений филаггрина при определенных ...unclassified

Modern realities of correction of skin barrier disorders in various diseases

Zhukova,

Tereshchenko,

Kasikhina

et al. 2024

Medicinskij sovet

View full text Add to dashboard Cite

Skin xerosis is a common symptom that indicates of impaired skin barrier function. Such diseases as atopic dermatitis (AD) and ichthyosis are associated with genetic mutations of epidermal differentiation genes, while in other diseases (contact dermatitis, eczema) epidermal barrier disorders occur as a result of inflammatory process in the skin, mechanical or chemical damage, significantly affecting the course of the pathological process. The article highlights modern data on the importance of the main structural protein of the stratum corneum filaggrin (FLG) and the role of its deficiency not only in dermatologic diseases, but also in the development of hyperresponsiveness. The main methods of correction of skin barrier disorders are emollients, which belong to the methods of basic therapy in AD and are recommended for the complex therapy of other pathological conditions accompanied by xerosis. At the present time, an innovative method has been developed, that allows not only to replace FLG deficiency, but also to activate and stimulate protein synthesis in the skin. In this regard, a unique dermatocosmetics product “Admera”, which belongs to the category of “emollients plus” due to the combination of all the necessary properties of the emollient and the presence of FLG synthesis modulator filagrinol, is of interest. Filagrinol is a proprietary complex of active ingredients that activate enzymes involved in dephosphorylation of the FLG predecessor profilaggrin and increase the concentration in the stratum granulosum сells of a histidine-rich glycoprotein, involved in the formation of the stratum corneum cytoskeleton. The article presents a review of clinical studies on the efficacy of Admera cream and presents our own clinical experience of its use in patients with AD and hand eczema.

show abstract

“…Риск развития ГА почти в 10 раз выше у пациентов с АтД, в то же время среди пациентов с ГА болезни атопического круга являются наиболее распространенными сопутствующими патологиями, имеющими прогностически неблагоприятное значение [67]. Выявлена положительная корреляция между наличием атопических заболеваний и тяжелым течением ГА, характеризующимся ранним началом, частыми длительными эпизодами с переходом в тотальную/универсальную форму до 75% случаев [70,71].…”

Section: ингибиторы Jak при коморбидности атопического дерматита и гн...unclassified

JAK-inhibitors in the therapy of comorbid diseases – atopic dermatitis and alopecia areata: literature review and experience of clinical practice

Potekaev,

Tereshchenko,

Gadzhigoroeva

2024

Medicinskij sovet

View full text Add to dashboard Cite

Atopic dermatitis (AtD) is currently considered as a systemic disease due to the fact, that disorders of innate and adaptive immune response, especially pronounced in severe course, are manifested not only in skin inflammation, but also can be realized in the development of other chronic diseases, including autoimmune profile. One of the autoimmune comorbid diseases in AtD is alopecia areata (AA), which is confirmed by epidemiologic data, clinical features and identification of common immune links of pathogenesis in the case of association of these diseases. Janus-kinase inhibitors, which represent a new class of targeted synthetic basic anti-inflammatory drugs, are currently the main pathogenetic treatments for severe forms of AtD and AA. Acting on several immune axes, these drugs selectively and reversibly modulate the signaling activity of key inflammatory cytokines, which makes them the most promising strategy for systemic therapy of these dermatoses, including in cases of their combination. The article covers the review of pathophysiology and application of first and second generation JAK-inhibitors in AtD and AA, including the analysis of their efficacy in the simultaneous presence of these pathological conditions. We present own observations of two patients with severe comorbid conditions AtD and AA, treated with the JAK-inhibitors abrocitinib and upadacitinib. These examples confirm the efficacy of Janus-kinase inhibitors in AtD and AA in real clinical practice and describe the experience of switching from one JAK-inhibitor of the first generation to another, selective JAK-inhibitor, as well as the effect of of these drugs on the course of both pathologies. Taking into account the necessity of long-term use of JAK-inhibitors, further study of their long-term efficacy and safety remains relevant.

show abstract

Bilateral Association Between Atopic Dermatitis® and Alopecia Areata: A Systematic Review and Meta-Analysis

Cited by 6 publications

References 83 publications

Disease burden, clinical management and unmet treatment need of patients with moderate to severe alopecia areata; consensus statements, insights, and practices from CERTAAE (Central/Eastern EU, Russia, Türkiye AA experts) Delphi panel

Disease burden, clinical management and unmet treatment need of patients with moderate to severe alopecia areata; consensus statements, insights, and practices from CERTAAE (Central/Eastern EU, Russia, Türkiye AA experts) Delphi panel

Modern realities of correction of skin barrier disorders in various diseases

JAK-inhibitors in the therapy of comorbid diseases – atopic dermatitis and alopecia areata: literature review and experience of clinical practice

Contact Info

Product

Resources

About